HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Deazaneplanocin a Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche

Abstract : Tumoral plasma cells has retained stemness features and in particular, a polycomb-silenced gene expression signature.Therefore, epigenetic therapy could be a mean to fight for multiple myeloma (MM), still an incurable pathology.Deazaneplanocin A (DZNep), a S-adenosyl-L-homocysteine hydrolase inhibitor, targets enhancer of zest homolog 2 (EZH2), acomponent of polycomb repressive complex 2 (PRC2) and is capable to induce the death of cancer cells. We show here that,in some MM cell lines, DZNep induced both caspase-dependent and -independent apoptosis. However, the induction of celldeath was not mediated through its effect on EZH2 and the trimethylation on lysine 27 of histone H3 (H3K27me3). DZNeplikely acted through non-epigenetic mechanisms in myeloma cells.In vivo, in xenograft models, andin vitroDZNep showedpotent antimyeloma activity alone or in combination with bortezomib. These preclinical data let us to envisage newtherapeutic strategies for myeloma.
Complete list of metadata

Contributor : Université Normandie Connect in order to contact the contributor
Submitted on : Thursday, May 27, 2021 - 5:01:42 PM
Last modification on : Wednesday, January 5, 2022 - 2:10:23 PM
Long-term archiving on: : Saturday, August 28, 2021 - 7:56:51 PM


Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution 4.0 International License



Jérémie Gaudichon, Francesco Milano, Julie Cahu, Laetitia Dacosta, Anton C. Martens, et al.. Deazaneplanocin a Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche. PLoS ONE, Public Library of Science, 2014, 9 (9), pp.e107009. ⟨10.1371/journal.pone.0107009⟩. ⟨hal-01762007⟩



Record views


Files downloads